February 2017

Contents

Editorial

• January/February 2017: Volume 18 Number 1/2

Supplements

• Pocket guides: A7 concertina leaflets

Conference reports

• 24th Conference on Retroviruses and Opportunistic Infections (CROI 2017), 13-16 February 2017, Seattle

• Pharmacokinetics and full phase 2 results for bictegravir, a new integrase inhibitor

• New NNRTI doravirine is non-inferior to darunavir/r in phase 3 treatment naive study

• NRTI GS-9131 resurfaces at CROI 2017: in vitro sensitivity to nuke-resistant HIV

• Dolutegravir exposure increases when fixed dose combination tablets are crushed

• Pharmacokinetics, safety and efficacy of dolutegravir in very young children

• Efavirenz, tenofovir and emtricitabine associated with fewest adverse birth outcomes in Botswana

• Adverse pregnancy outcomes and risk factors in the PROMISE trial

• Women on lopinavir/ritonavir-based regimens at conception at higher risk of preterm delivery in UK study

• No increase in adverse birth outcomes with maternal TDF/FTC in US study

• Dolutegravir monotherapy studies halted due to integrase resistance: dual therapy studies continue

• No evidence of accelerated brain ageing in HIV positive people on effective ART

• Acute infection with wild-type HIV on PrEP with good drug levels

• Fit for purpose: antiretroviral treatment optimisation Feb 2017

• Seattle-lite: pre-conference workshops – watch online

Antiretrovirals

• US Stribild label updated: new indication to include patients age 12 and older

• Option to take crushed Stribild tablets with food or enteral nutrition

• ART adherence in first four months predicts long-term viral suppression in 12-year study

• Effects of ART initiation on human papillomavirus antibody response

Treatment access

• Sutezolid added to MPP as potential TB drug

• AT LAST: Gay men and transgender people in England get vaccine to prevent genital warts and anal cancer – impressive pilot results

Pregnancy

• Pregnancy common in ART trials in sub-Saharan Africa despite exclusion criteria

Guidelines

• Drug-drug interactions and hormone therapy for gender transitioning

• New NICE/PHE testing guidelines (2017)

• WHO guidelines on HIV self-testing and partner notification (2017)

Coinfections and complications

• Rosuvastatin for chronic obstructive pulmonary disease (COPD) in people with HIV

HIV prevention and transmission

• Brighton heads towards zero HIV: first UK city with UN Fast Track status

• Four London clinics report dramatic drops in HIV incidence in gay men: PrEP, early testing and early ART likely to be key

• NHS England fudges PrEP access and delays on-demand access to PrEP by years; blocks doctors from prescribing PrEP now

• Update on PrEP in Scotland

• New York reports fewer HIV diagnoses in 2015: target to reduce new infections by 75% by 2020

Basic science and immunology

• Soluble CD163 as a marker of CMV mediated immune activation

• Levels of CMV antibody are linked to HIV progression and immune activation in Ugandan women

PDFs

• January/February 2017: Volume 18 Number 1/2